Anzeige
Mehr »
Login
Mittwoch, 07.06.2023 Börsentäglich über 12.000 News von 690 internationalen Medien
NuGen Medical: 8,4 Mio. CAD Umsatz von einem einzelnen Kunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PQNF | ISIN: US61023L1089 | Ticker-Symbol: 1IY
Tradegate
06.06.23
20:04 Uhr
0,850 Euro
-0,020
-2,30 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MONOPAR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MONOPAR THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8400,88006.06.
0,8350,88506.06.

Aktuelle News zur MONOPAR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MONOPAR THERAPEUTICS Aktie jetzt für 0€ handeln
DoWhere Monopar Therapeutics Stands With Analysts-
DoMonopar Therapeutics - 8-K, Current Report5
11.05.Monopar Therapeutics - 8-K, Current Report-
11.05.Monopar Therapeutics - 10-Q, Quarterly Report-
11.05.Monopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments253WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinicalstage biopharmaceutical company focused on developing proprietary therapeutics...
► Artikel lesen
29.03.Monopar puts a stop to its chemo complication drug; Exicure explores future transactions1
28.03.Monopar spikes chemo side effect drug after disappointing phase 2/3 interim analysis1
28.03.Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication1
28.03.Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today?-
28.03.Monopar Therapeutics Shares Are Tumbling: What's Going On?-
28.03.Biomea, Oscar top healthcare gainers; Monopar, OncoSec lead losers' pack1
28.03.Monopar Therapeutics Inc.: Monopar to Present at the Jefferies Radiopharma Innovation Summit-
28.03.Monopar To Discontinue Phase 2b/3 VOICE Trial Along With Active Development Of Validive1
28.03.Monopar stock crashes ~50% as Validive program gets axed after trial failure2
27.03.Monopar Therapeutics Inc.: Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis276WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...
► Artikel lesen
23.03.Monopar Therapeutics GAAP EPS of -$0.22 misses by $0.02-
23.03.Monopar Therapeutics - 8-K, Current Report-
23.03.Monopar Therapeutics - 10-K, Annual Report-
23.03.Monopar Therapeutics Inc.: Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments168Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill., March...
► Artikel lesen
17.03.Pre-market Movers: Enzo Biochem, HUB Cyber Security, Sarepta Therapeutics, Monopar Therapeutics, ThermoGenesis831MEMPHIS (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).In the GreenEnzo Biochem, Inc. (ENZ) is up over 81% at $2.16. HUB...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1